ATOS shows severe financial deterioration with revenue collapsing 99.7% while R&D expenses surged 50.1%, burning through $30M in cash and equity.
The company appears to be in a critical phase transition from a revenue-generating entity to a pure R&D burn operation focused on (Z)-endoxifen development. With cash declining from $71M to $41M and stockholders' equity dropping 45%, ATOS has limited runway to reach meaningful clinical milestones. The dramatic revenue collapse suggests they may have exited previous business lines to focus entirely on drug development.
ATOS experienced a dramatic financial transformation with revenue virtually disappearing (down 99.7% to just $2K) while R&D expenses increased 50.1% to $21.2M, indicating a complete pivot to drug development. The company burned through approximately $30M in cash (down 42% to $41.3M) and saw stockholders' equity decline 45% to $39.4M, while total liabilities increased 66% to $8.3M. This financial profile signals a biotech company in intensive development mode with a rapidly diminishing cash runway and no meaningful revenue generation.
Debt increased 745.6% — substantial leverage increase; assess whether deployed for growth or covering losses.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Receivables surged 114.2% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Revenue declined 99.7% — significant demand weakness or market share loss warrants investigation.
Liabilities grew 66.2% — significant increase in debt or obligations, assess impact on financial flexibility.
Current liabilities surged 66.2% — significant near-term obligations; verify ability to meet short-term debt.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
R&D investment increased 50.1% — signals commitment to future product development, though near-term margin impact.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash declined 41.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →